Capecitabine

卡培他滨

Report date: 2026/05/21 20:00:22
NME

Base Information

Drug NameCapecitabine
Drug Alias NameCapecitabina卡培他宾CapecitabinumCapecitabine RDTXelox +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionThymidylate synthase inhibitors
TargetsThymidylate synthase
Therapy Area/IndicationsBone metastasesMetastatic breast cancerCNS Embryonal Tumor +[47] 
Global Approved IndicationsStomach NeoplasmsColonic NeoplasmsColorectal Neoplasms +[4] 
Approved Indications in ChinaColorectal NeoplasmsBreast Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date1998/04/30
Country/TerritoryBelgiumCanadaUnited States +[30] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteInstitut De Cancérologie Lucien NeuwirthTranslational Breast Cancer Research Consortium +[28] 
Inactive CompaniesUniversity Of Florida HealthRadboud University Medical CenterUniversity Of California San Francisco +[35] 
Active IndicationsMetastatic breast cancerSkin NeoplasmsLaryngeal Neoplasms +[18] 
Inactive IndicationsBone metastasesCNS Embryonal TumorGastroenteropancreatic neuroendocrine tumor +[29] 

Other Information

ATC CodeL01BC06
Related LinksWikipediaDrugBankKEGG